Cathy Turner, Project Manager for DMD Care UK at the John Walton Muscular Dystrophy Research Center at Newcastle University, discusses the TREAT-NMD Advisory Committee for Therapeutics (TACT).
TACT was established in 2009 with the goal of providing advice to organizations in the rare neuromuscular disease therapy development space. The committee consists of experts in various fields that are imperative for the success of a clinical trial or the development of a treatment. These include regulatory advisors, statisticians, clinical experts, and patient representatives, among many others. A bespoke panel is constructed for each individual project to best fit the specific needs of the company or academic group.
As noted by Ms. Turner, the model being used by TACT has applications to a number of rare conditions, not just neuromuscular disorders.
To learn more about TACT and how to apply, click here.
For more information on rare musculoskeletal disorders, visit https://checkrare.com/diseases/musculoskeletal-diseases/